Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 29 | 1,032 | 44% |
| 2020 | 16 | 900 | 46% |
| 2021 | 17 | 807 | 49% |
| 2022 | 20 | 871 | 51% |
| 2023 | 19 | 856 | 53% |
| 2024 | 21 | 884 | 54% |
| 2025 from claims | – | 1,001 809–1,175 | 55% |
| 2026 forecast | – | 1,019 798–1,279 | 55% |
| 2027 forecast | – | 1,032 765–1,365 | 56% |
| 2028 forecast | – | 1,046 741–1,444 | 56% |
| 2029 forecast | – | 1,060 721–1,520 | 57% |
| 2030 forecast | – | 1,074 704–1,594 | 57% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in Arizona; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 98% inpatient hospital, 2% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 46 | 2,550−2.4%/yr | −2.4%/yr | 0.7 | 0% | 2,560 in 2030+0.1%/yr |
| Washington | 15 | 658−6.5%/yr | −6.5%/yr | 0.8 | 0% | 680 in 2030+0.6%/yr |
| Oregon | 8 | 425−4.9%/yr | −4.9%/yr | 1.0 | 0% | 460 in 2030+1.4%/yr |
| Nevada | 11 | 315−0.4%/yr | −0.4%/yr | 1.1 | 0% | 610 in 2030+11%/yr |
| Colorado | 5 | 302−7.5%/yr | −7.5%/yr | 0.6 | 0% | 280 in 2030−1.5%/yr |
| Idaho | 7 | 243+15%/yr | +15%/yr | 1.2 | 0% | 590 in 2030+16%/yr |
| Utah | 2 | 170−2.8%/yr | −2.8%/yr | 0.8 | 0% | 110 in 2030−6.4%/yr |
| Montana | 4 | 162−1.2%/yr | −1.2%/yr | 0.8 | 0% | 170 in 2030+1.3%/yr |
| New Mexico | 1 | 111−8.3%/yr | −8.3%/yr | 0.5 | 0% | 150 in 2030+5.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 94 | 10,087−0.8%/yr | −0.8%/yr | 13.02.6× | 100% | 10,200 in 2030+0.2%/yr |
| Peripheral arterial intervention | 38 | 4,850−6.8%/yr | −6.8%/yr | 6.21.3× | 74% | 4,560 in 2030−1%/yr |
| Dialysis access | 33 | 3,680−7.6%/yr | −7.6%/yr | 5.21.1× | 88% | 4,140 in 2030+2%/yr |
| Thrombectomy, IVC filters & venous stents | 11 | 1,180+4.1%/yr | +4.1%/yr | 1.61.4× | 19% | 1,490 in 2030+3.9%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 322−6.9%/yr | −6.9%/yr | 0.41.4× | 0% | 370 in 2030+2.5%/yr |
Carotid revascularization in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Boston Scientific leads with 70% of company spending on these surgeons in 2025, −22 pts on 2024.
In 2025, 6 companies reported engagement with Arizona’s surgeons worth $14K in consulting, speaking, meals and travel tied to these products, about $650 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.